Page last updated: 2024-12-05

2,3-dihydroxynaphthalene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,3-naphthalenediol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7091
CHEMBL ID205007
CHEBI ID38135
SCHEMBL ID28653
MeSH IDM0151551

Synonyms (54)

Synonym
einecs 202-156-7
ai3-18148
brn 0742375
nsc 8707
2,3-dihydroxynaphthlene
92-44-4
nsc8707
naphthalene-2,3-diol
2,3-naphthalenediol
2,3-dihydroxynapthalene
nsc-8707
wln: l66j cq dq
2,3-dihydroxynaphthalene
CHEBI:38135 ,
inchi=1/c10h8o2/c11-9-5-7-3-1-2-4-8(7)6-10(9)12/h1-6,11-12
2,3-dihydroxy-naphthalene
STK370868
2,3-dihydroxynaphthalene, >=98.0% (hplc)
D0593
CHEMBL205007
AKOS000120222
A844237
2,3-dihydroxy naphthalene
o9u131030z ,
unii-o9u131030z
4-06-00-06564 (beilstein handbook reference)
FT-0609670
dihydroxynaphthalene, 2,3-
2,3-naphthalenediol [inci]
3-hydroxy-2-naphthol
2,3dihydroxynaphthalene
bdbm36290
SCHEMBL28653
naphthalenediol-(2,3)
dtxsid2043903 ,
NCGC00356949-01
dtxcid0023903
tox21_303850
cas-92-44-4
W-100288
AC-24461
mfcd00004073
F1908-0110
2,3-dihydroxynaphthalene, technical, >=90% (hplc)
SY015230
Q27117387
AS-12863
d48 ,
2-hydroxy-3-naphthol
AC2509
CS-W013274
EN300-20357
HY-W012558
Z104477860
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphthalenediolA class of naphthalenediols that consists solely of naphthelene with any two of its hydrogens replaced by hydroxy groups. A 'closed class'.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency7.76060.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency7.76060.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency53.13430.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency34.60440.000221.22318,912.5098AID1259243; AID1259247
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency61.13060.000657.913322,387.1992AID1259377; AID1259378
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.44830.001530.607315,848.9004AID1224841
Histone H2A.xCricetulus griseus (Chinese hamster)Potency126.79300.039147.5451146.8240AID1224845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID261690Antiproliferative activity against human fibroblast HFL1 cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Selective antiproliferative activity of hydroxynaphthyl-beta-D-xylosides.
AID261691Antiproliferative activity against human bladder carcinoma T24 cells2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Selective antiproliferative activity of hydroxynaphthyl-beta-D-xylosides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (6.67)18.7374
1990's2 (13.33)18.2507
2000's5 (33.33)29.6817
2010's7 (46.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.06 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index34.57 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]